SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer
Conditions: ER Positive/HER2 Low Breast Cancer Interventions: Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection Sponsors: Shengjing Hospital; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hospitals | Neoadjuvant Therapy | Research